Drug Interactions between Concerta and Parlodel
This report displays the potential drug interactions for the following 2 drugs:
- Concerta (methylphenidate)
- Parlodel (bromocriptine)
Interactions between your drugs
No interactions were found between Concerta and Parlodel. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Concerta
A total of 198 drugs are known to interact with Concerta.
- Concerta is in the drug class CNS stimulants.
- Concerta is used to treat the following conditions:
Parlodel
A total of 444 drugs are known to interact with Parlodel.
- Parlodel is in the following drug classes: dopaminergic antiparkinsonism agents, prolactin inhibitors.
- Parlodel is used to treat the following conditions:
Drug and food interactions
bromocriptine food
Applies to: Parlodel (bromocriptine)
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References
- Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
- (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
- (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
methylphenidate food
Applies to: Concerta (methylphenidate)
GENERALLY AVOID: Alcohol may exacerbate the adverse central nervous system effects of psychoactive drugs, including methylphenidate.
GENERALLY AVOID: Consumption of alcohol while taking certain sustained-release formulations of methylphenidate may cause rapid release of the drug, resulting in increased systemic levels of methylphenidate. In vitro studies have been conducted using Metadate CD 60 mg and Ritalin LA 40 mg capsules, as well as Concerta 18 mg tablet. At an alcohol concentration of 40%, an increase in the release rate of methylphenidate was observed in the first hour for Metadate CD and Ritalin LA, resulting in 84% and 98% of the methylphenidate being released, respectively. In contrast, there was no increased release of methylphenidate in the first hour for Concerta. These results are considered to be representative of the other available strengths of the corresponding product.
MANAGEMENT: Patients treated with methylphenidate should be advised to avoid alcohol or medications that contain alcohol.
References
- (2022) "Product Information. Metadate CD (methylphenidate)." Celltech Pharmaceuticals Inc
- (2002) "Product Information. Concerta (methylphenidate)." Alza
- (2013) "Product Information. Ritalin LA (methylphenidate)." Quality Care Products/Lake Erie Medical
bromocriptine food
Applies to: Parlodel (bromocriptine)
MONITOR: Nicotine may cause vasoconstriction in some patients and potentiate the ischemic response to ergot alkaloids.
MANAGEMENT: Caution may be advisable when ergot alkaloids are used in combination with nicotine products. Patients should be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.
References
- (2001) "Product Information. Migranal (dihydroergotamine nasal)." Novartis Pharmaceuticals
- (2004) "Product Information. Cafergot (caffeine-ergotamine)." Novartis Pharmaceuticals
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.